Why Is VERA THERAPEUTICS IN A (VERA) Stock Down Today?
By the Top Tier Newswire AI Desk · September 16, 2026 at 12:24 PM ET · reviewed against 17 wire stories
VERA THERAPEUTICS IN A (VERA) is down -6.06% in the latest session. Our newswire has captured 17 stories on VERA across 12 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why VERA stock is down today
VERA stock is down 6.06% at $31.63 as of the latest update. The decline follows a volatile intraday session marked by early strength and a sharp reversal. The stock opened at $33.75 but failed to sustain momentum, reaching a high of $34.00 shortly after the market opened before falling to a session low of $31.60. The drop comes after a series of positive developments around the company's Trutakna drug, including positive Phase 3 trial results and continued analyst optimism, but appears to reflect investor caution and profit-taking.
What Happened
Vera Therapeutics announced that its Trutakna drug met all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 IgA nephropathy trial. This milestone led to a 13% rise in the stock earlier in the week. The company also presented at the Morgan Stanley 24th Annual Global Healthcare Conference, where executives detailed the drug’s progress. Analysts from Raymond James and TD Cowen reiterated positive ratings, with Raymond James maintaining a Strong Buy and TD Cowen a Buy. Despite these developments, the stock has seen a reversal in sentiment, with investors taking profits after a recent rally.
What The Data Shows
The stock opened higher but has since reversed course, trading at $31.60 with a volume of 1.1 million shares, which is 0.6 times the 3-month daily average. The stock is currently trading within its 52-week range of $22.72 to $56.05 and has declined 4.6% over the past eight sessions. Options activity has been skewed to the put side, with $11.3 million in put premiums versus $0 in call premiums, and the largest single print at $5.6 million. Additionally, the CEO, Marshall Fordyce, has sold shares on three separate occasions in the last 90 days, totaling $3.3 million.
What To Watch
Investors should monitor the FDA's review process for Trutakna, as well as any further analyst commentary or corporate updates. The stock is currently unprofitable with an EPS of -5.89 and a market cap of $2.5 billion.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
VERA · today's session (5-min) · -4.92% vs prior close · updated 5:21 PM ETAI sentiment, last 36h · averaged over 17 stories · 66/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
21h agoSeeking AlphaBULLISH 56Product/PR
Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Vera Therapeutics, Inc. (VERA) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 5:35 PM EDTCompany ParticipantsMarshall Fordyce -...
1d agoSeeking AlphaBULLISH 56Product/PR
Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data
Vera Therapeutics, Inc. gets FDA accelerated approval for Trutakna in IgA nephropathy, but competition and pricing risk remain. Click for this VERA update.
1d agoBarron'sBULLISH 73Product/PR
Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
Vera Therapeutics takes a step toward securing full Food and Drug Administration approval for its injectable kidney drug, Trutakna.
Vera Therapeutics stock maintained at Strong Buy by Raymond James
Vera Therapeutics stock maintained at Strong Buy by Raymond James
1d agoThe FlyBULLISH 67Product/PR
Vera Therapeutics ORIGIN 3 study results positive, says Raymond James
1d agoInvestorsHubBULLISH 73Product/PR
Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints
Vera Therapeutics shares rise 13% after TRUTAKNA meets all prespecified endpoints in the final efficacy analysis of the ORIGIN 3 IgA nephropathy trial.
1d agoTechStock²BULLISH 78Product/PR
TRUTAKNA Cut ORIGIN 3 Kidney-Progression Risk by 76%; FDA Review Comes Next
Vera Therapeutics shares jumped 9.4% to $37.25 in Nasdaq premarket trading at 9:29 a.m. ET Tuesday after its confirmatory Phase 3 trial reported slower kidney-function loss with TRUTAKNA than with placebo. The move followed a $34.05 Monday close. The company’s September 15 ORIGIN 3 release addresses the question left open when the Food and Drug…
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →